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Abstract—Although drug-eluting stents (DES) are now
widely used for the treatment of coronary heart disease,
there remains considerable scope for the development of
enhanced designs which address some of the limitations of
existing devices. The drug release proﬁle is a key element
governing the overall performance of DES. The use of
in vitro, in vivo, ex vivo, in silico and mathematical models has
enhanced understanding of the factors which govern drug
uptake and distribution from DES. Such work has identiﬁed
the physical phenomena determining the transport of drug
from the stent and through tissue, and has highlighted the
importance of stent coatings and drug physical properties to
this process. However, there is limited information regarding
the precise role that the atherosclerotic lesion has in
determining the uptake and distribution of drug. In this
review, we start by discussing the various models that have
been used in this research area, highlighting the different
types of information they can provide. We then go on to
describe more recent methods that incorporate the impact of
atherosclerotic lesions.
Keywords—Drug-eluting stents, Atherosclerosis, Drug up-
take, Drug distribution, In vitro models, In vivo models,
Mathematical models, Computational models, Drug trans-
port, Arteries.
INTRODUCTION
Although drug-eluting stents (DES) have revolu-
tionised the treatment of coronary heart disease, their
performance is severely limited in some patient
groups,3 and lesion types.2 Moreover, delayed
endothelialisation remains a concern.24 Consequently,
considerable research remains dedicated towards the
development of improved DES. There are a number of
key aspects of DES that contribute to the overall
performance of the device, and each must be opti-
mised, in an integrated fashion, for successful perfor-
mance. The stent platform, material and coating
clearly play an important role in performance,34,52,54
with recent improvements including the use of thinner
struts and a variety of different metal alloys.19,39 Most
recently, fully bioresorbable stents have been devel-
oped, consisting entirely of biodegradable polymers or
metals [see Wiebe et al. (2014) for a recent review].72
The drug that is delivered from the stent is also of
crucial importance, and although a great variety of
drugs have been investigated [see Khan et al. (2012) for
a recent review],29current clinically used DES rely on
the use of sirolimus analogues and paclitaxel. In this
review, we focus on the challenge of optimising the
release and uptake of drug from the stent surface into
the vessel wall. We will ﬁrstly describe the current
models used to characterise this aspect of DES design
and performance, before going on to describe recent
efforts to incorporate atherosclerosis into such models.
MODELLING DRUG RELEASE AND
DISTRIBUTION
Stent-based drug release and the subsequent uptake
and distribution within arterial tissue is a complex
phenomenon, involving a series of diﬀerent but often
interdependent mechanisms (Fig. 1). Several models
are available, which attempt to describe at least some
aspects of this phenomenon. Schwartz et al. 200856
made a series of recommendations on a variety of pre-
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clinical tests that should be performed during DES
development and evaluation. These range from simple
in vitro dissolution tests through to whole animal
studies. In the ﬁrst part of this review, we will describe
the current state of the art within each test type. We
will also consider the emerging role that ex vivo models
and computational techniques are playing in this area.
In Vitro Models
In vitro drug release proﬁle models are an integral
part of the DES development process. They are par-
ticularly useful for establishing the reproducibility of
the coating procedure and drug release. This can be
readily assessed by using accelerated release methods,
where solvents and/or surfactants are added to the
release medium to increase the rate of drug release.28
In addition to their importance for quality control
purposes, such methods can also provide useful in-
sights into the mechanisms governing drug release
from the coating. Mechanistic information can also be
gained from the use of in vitro models that seek to
mimic in vivo drug release. A number of requirements
need to be met in order that in vitro release resembles
the in vivo situation as closely as possible and these
should take into consideration the drug being investi-
gated (see Schwartz et al. 2008 and Schwartz et al. 2002
for recommendations).55,56
The simplest in vitro drug release methods incubate
the stent, or stent substitute, in release medium and
transfer the sample to fresh medium at predetermined
time points. It is generally recommended that the
volume of the release medium should be selected to
ensure inﬁnite sink conditions are maintained as clo-
sely as possible, thus better mimicking the in vivo sit-
uation and preventing the drug from saturating the
release medium, which would affect the dissolution
rate.55,56 The release media used can alter the release
proﬁle, as the drug and/or polymer used can be sen-
sitive to changes in media composition, with such ef-
fects being a common feature of accelerated drug
release assays. As an example, the addition of solvents
to the release media increased solubility and dramati-
cally altered in vitro paclitaxel release from the
TAXUS stent, effects that were dependent on both the
solvent type and concentration used.27 A similar effect
was highlighted by Kamberi et al. 2009, who found
that increasing acetonitrile concentration within the
release medium increased the total drug elution from
an everolimus-eluting stent.28 Furthermore, the
porosity of the polymer coating can be affected by the
presence of solvent in the release media with possible
implications on the drug release proﬁle. It was found
that the porosity of the polymer coating was increased
in stents placed in dissolution media containing ace-
tonitrile, whilst the structure remained unaltered in
control media.28
FIGURE 1. A simplified diagram illustrating the key arterial ultrastructures and the transport forces involved in drug distribution
within a stented artery. Drug is transported through the vessel wall by various forces and partitions to both specific and non-
specific binding sites. Figure adapted from Yang et al. 2006.73
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In the case of sirolimus, the drug release proﬁle has
been shown to be dependent on both drug stability and
solubility in the release medium. Indeed, cumulative
release of sirolimus was maximal in a normal saline-
isopropyl alcohol mix, compared to both phosphate
buﬀer (PB) and phosphate buﬀered saline (PBS) over
an extended 75 day period from a polymer free stent.
This diﬀerence was most likely due to the pH of PB
and PBS (being pH 7.4), causing hydrolysis of the
sirolimus.30,45
Just as careful selection of the release media can
provide accelerated release; it can also be used to
produce in vitro release proﬁles that are useful pre-
dictors of in vivo release. This is particularly important
when the drug being investigated is known to bind to
proteins, and/or undergoes degradation. In human
plasma, cumulative release of sirolimus reached a lag
phase by 1 week and only increased marginally up to
the 25 day end point of the experiment, a pattern
thought to be due to degradation of the drug.30 Long
term release of everolimus into porcine serum was
assessed in order to produce a biorelevant release
proﬁle.28 To circumvent the problem of detection and
degradation of the drug in serum the investigators
inferred the serum concentration at each sampling
point from the drug remaining on the stent. Addi-
tionally, this release proﬁle correlated well with a
short-term release proﬁle which used solvents in the
release medium. Such an approach allows for a
reduction in the time required to obtain robust release
proﬁles from weeks to hours.
The standard in vitro dissolution tests we have de-
scribed so far lack the presence of a stent-artery
interface. Whilst these can provide useful information
on the reproducibility of the coating process and in-
deed on the mechanisms of drug release,35 the release
proﬁle can only be indicative of the likely in vivo sit-
uation and cannot account for transfer of drug from
the stent surface into tissues. More recent develop-
ments have attempted to address this limitation
through the use of ﬂow-cells that mimic the stent-ar-
tery interface.46,57 These models contain a chambered
hydrogel with a hollow central aperture, into which a
stent can be deployed. This allows quantiﬁcation of
drug diffusion and distribution into the hydrogel
compartment over time. A closed loop allows contin-
uous ﬂow through of media which can be serially
sampled and drug release into the compartment mea-
sured.46 Additional work with this model has described
spatial distribution of model substances within the
hydrogel compartment which agreed well with ﬁnite
element analysis of diffusion coefﬁcients.57
An alternative model has been developed to assess
the impact of ﬂow on drug release from a single stent
strut through a hydrogel.47 The primary purpose of
this work was to validate the ﬁndings from computa-
tional modelling that highlighted the contribution of
ﬂow around stent struts to drug uptake and distribu-
tion. Furthermore, this model sought to overcome the
limited ability of computational models to incorporate
the complex dynamics of pulsatile ﬂow, and high-
lighted the importance of strut geometry on drug dis-
tribution. Distribution was dependent on the strut
aspect ratio which determined the magnitude of
regions of ﬂow recirculation, and therefore concen-
tration of drug within these regions. Further work with
this model highlighted the importance of ﬂow rate, as
halving the mean vessel Reynolds number increased
the uptake of drug by around 30%. Additionally,
computational modelling indicated that pulsatile ﬂow
had a negligible impact on the overall mass of drug
uptake in an idealised stent placement. However,
increasing degrees of strut malapposition led to a de-
crease in drug uptake and distribution due to increased
magnitude of regions of ﬂow recirculation, causing
decreased drug concentration in these regions.47
The use of artery mimics in these models means they
do not adequately capture the eﬀects of speciﬁc drug
binding sites, or physiological drug transport mecha-
nisms. Furthermore, they do not replicate the multi-
layered arterial wall structure and tend to neglect both
anisotropic diﬀusion and the eﬀects of transmural
pressure gradient.46–48,57 However, there are model
systems available in which some of these parameters
can be independently assessed. For example, drug
binding to speciﬁc sites can be readily evaluated
in vitro. Early work by Khu et al. (2000)31 described
the complex binding of paclitaxel using complimentary
in vitro and computational modelling. They found both
extracellular and intracellular binding to be dependent
on drug loading concentration and cell density in a
time dependent manner. Similarly, sirolimus has also
been investigated in vitro and shown to bind to the
intracellular target FK-binding protein 12 (FKBP-
12).4 The cellular uptake and release of sirolimus have
also been investigated, by incubating human venous
smooth muscle cells in different sirolimus concentra-
tions (5, 15 or 25 lg/mL).77 Equilibrium was rapidly
reached within 30 min of incubation, and the drug
remained within the cells over a 5 h period, suggesting
that binding had taken place although this was not
measured directly. Drug release from the cells was ra-
pid, with an equilibrium level achieved within 60 min
and this was maintained for the remainder of the 5 h
incubation period. The data from these experiments
was ﬁtted to a ﬁrst order kinetics equation which
indicated that drug transport into and out of the cells
was predominantly governed by diffusion.
There is emerging research investigating the release
of drug from stents in real time which has been made
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possible by the use of advanced imaging techniques.
Using correlated confocal Raman and atomic force
microscopy, Biggs et al.5 mapped the chemical com-
position and topography of the surface and subsurface
of the CYPHER stent. They were able to correlate
sirolimus elution with structural changes to the sur-
faces, where the formation of porous regions had taken
place.5 Carlyle et al.7 employed a vessel simulating
loop which incorporated ﬂow analogous to a coronary
artery, mimicking pressure, shear stress and velocity,
and a biorelevant release medium, to investigate re-
lease from an absorbable sirolimus eluting stent coat-
ing (AC-SES). Here they imaged the stent,
macroscopically, through the surface of the ﬂow loop
and visualised changes to the stent polymer coating
which softened and dispersed over time. Computa-
tional modelling indicated that polymer dispersion
would lead to greater lateral distribution of drug
within the artery wall due to increased contact between
the stent coating and the artery.7
In Vivo Models
Ultimately, an improved understanding of DES
drug release kinetics and mechanisms requires the use
of animal models. Many such models have been used
in the development and assessment of DES. These
range from smaller species, including the mouse
aorta,1,11 up to larger models such as the pig coronary
artery.69,70 For pre-clinical assessment of safety, it is
generally accepted that the pig coronary artery is the
most appropriate model.56 It is beyond the scope of
this review to consider each model in detail and our
discussion will focus initially on the use of rabbit and
pig stent models for investigation of drug pharma-
cokinetics. However, the use of smaller models may
permit the investigation of speciﬁc aspects of disease,
such as speciﬁc lesion subtypes and changes to the
vessel ultrastructure, which may impact device per-
formance.
Pig Models
The pig coronary artery model is recognised as the
gold standard animal model.56 It is therefore widely
used for pre-clinical safety and efﬁcacy assessment al-
though it has been less well used for characterising
drug pharmacokinetics. Watt et al. 2013 characterised
drug release from a novel polymer-free anti-oxidant,
succinobucol-eluting stent. Drug remaining on the
stent and drug within arterial tissue were measured at
multiple time points up to 28 days. The elution of the
drug in vivo displayed a biphasic release proﬁle with
60% of load eluted within the ﬁrst week with a further
20% over the next 2 weeks. This study also found that
tissue succinobucol content reduced over time indi-
cating that clearance rate exceeded elution rate.70
Carlyle et al.7 were able to demonstrate extended and
controlled drug release from an AC-SES using the pig
model. This study highlighted the value of assessment
of drug release over long periods of time, since it was
found that although 97% of the release had occurred
by 45 days, drug levels were still found in signiﬁcant
quantities within arteries after 90 days.7
Tzafriri et al. 201264 also used the pig model,
alongside computational modelling, to investigate the
pharmacokinetics of two different sirolimus-eluting
stents. The study investigated the tissue drug binding
eluted from the CYPHER and NEVO stents. Both
devices eluted a similar amount of drug over a 30 day
period in vitro, with the former displaying a biphasic
release proﬁle and the latter a linear steady elution
rate. Despite this initial burst the authors found that
CYPHER stents produced consistently lower sirolimus
tissue content from 3 to 30 days. Computational
modelling was used to address this apparent discrep-
ancy and it was predicted that receptor saturation was
similar in arteries implanted with either stent, which
may help explain the similar clinical efﬁcacy reported
for both devices. The insights provided by this study,
achieved through the combined use of in vivo and
computational models, demonstrate the value of
adopting a variety of complementary approaches to
furthering our understanding of stent-based drug
delivery.
Rabbit Models
The rabbit is a species routinely used for the inves-
tigation of atherosclerosis, and has been used exten-
sively for the investigation of in-stent restenosis (ISR).
Due to its wide spread use, the rabbit iliac artery stent
model is well characterised8 and the ﬂow dynamics and
vascular response compare favourably to the pig
coronary artery. In particular, re-endothelialisation
occurs at a rate comparable with humans in the rabbit
model whereas it is accelerated in the pig.49
This model was used to evaluate the in vivo phar-
macokinetics of the Xience Prime everolimus eluting
stent (EEV) and the Endeavour Resolute slow-release
zotarolimus eluting stent (R-ZES) in healthy arteries.
The authors reported a consistent and signiﬁcantly
greater level of arterial drug deposition in rabbits
receiving R-ZES compared to EES over a 90 day
period, despite similar in vitro release proﬁles of the
two stents. The difference was attributed to the
increased lipophilicity of zotarolimus over everolimus,
and conﬁrms results from ex vivo and in vitro experi-
ments. Furthermore, as in the pig studies described
earlier, although the tissue drug content decreased over
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time, drug was still present after 90 days despite the
majority having been eluted after 28 days.74
It is clear that the strength of in vivo models is that
they are most relevant to the clinical situation. How-
ever, ethical concerns and cost implications mean that
evaluation of drug release at the multiple time points
necessary to fully characterise drug release, is neces-
sarily limited to a small number of studies. Moreover,
the majority of the models being used currently do not
have disease that is comparable to the atherosclerotic
plaques found in patients with coronary heart disease.
Ex Vivo Models
The use of ex vivo models is particularly appealing,
because they enable the mechanisms governing drug
transport within stented arteries to be explored in a
way that is simply not possible in vivo. This approach
allows for the control of some variables, such as ﬂow
rate and pulsatility, which can be altered to closely
replicate the in vivo situation.
The role of convective and diﬀusive transport and
physical properties of drug and tissue on uptake and
distribution were described in work by Creel et al.9 in
ex vivo perfused calf carotid arteries. The setup consists
of an extravascular bath into which an upper reservoir,
at sufﬁcient height to produce a pressure gradient,
ﬂows via tubing (Fig. 2 as described by Lovich et al.)33
In this system, it was found that the distribution of the
hydrophobic drug paclitaxel was dependent on site of
delivery, perivascular vs. endovascular, and time.
Furthermore, paclitaxel was retained within the tissue
at around 20 times higher concentration than the
hydrophilic drug heparin, highlighting the importance
of drug physicochemical properties in tissue uptake
and distribution.9 Further work with this model
incorporated a balloon expanded DES and high-
lighted the heterogeneity of drug distribution. Indeed,
there were vast differences in drug concentration
between segments proximal and distal to the stent
struts.23 The importance of vessel wall multi-layered
geometry and ultrastructure on drug diffusion was
described using this model, and this highlighted the
importance of anisotropic diffusion.22 The presence of
disease will signiﬁcantly disrupt the normal vessel
structure. How this might affect drug transport is
discussed later.
Drug binding and distribution have also been eval-
uated in excised arterial tissue incubated in drug
solutions. The importance of binding sites was evident
for paclitaxel which was distributed in a non-uniform
fashion after 60 h incubation, whereas sirolimus was
evenly bound across the tissue. These diﬀerences were
determined to be dependent on the abundance and
location of speciﬁc and non-speciﬁc binding sites.32
Whilst these models have provided useful insights
into the mechanisms governing arterial drug transport
and distribution, they do not mimic all aspects of the
in vivo situation and in particular it is generally only
practical to maintain such ex vivo set ups for up to a
few days. Given these various limitations, mathemati-
cal and computational analysis of drug release have
emerged as useful tools for understanding the perfor-
mance of existing devices and optimising future de-
vices.
Computational Models
Mathematical and computational models of drug
release and distribution range in complexity, from
well-deﬁned 1D simpliﬁcations that can be solved
analytically, through to 2D and 3D representations
that require numerical methods and ﬁnite element
analysis approaches. State of the art in this ﬁeld was
recently reviewed by McGinty (2014).35 The models
can be roughly separated into three categories: those
which focus solely on modelling drug release in a
controlled environment; those which concentrate on
modelling drug transport in arterial tissue; and those
which couple the drug release and tissue transport to
simulate the in vivo environment. In the ﬁrst of these
categories, simple 1D mathematical models of drug
release from non-absorbable polymer-coated stents
have been shown to agree well with controlled exper-
iments.20,37,75 In addition, 1D models have been pre-
FIGURE 2. Diagram of an ex vivo perfusion circuit. The setup
consists of an extravascular bath containing the excised ar-
tery. The bath is supplied buffer by an upper reservoir via
tubing, into which flow is recirculated via a peristaltic pump.
The upper reservoir height, DH, can be adjusted to alter flow
rate and transmural pressure. Figure adapted from Lovich
et al. 1995.33
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sented for drug release from biodegradable polymer
coatings50 and most recently from polymer free
stents.38 In the second category, models of drug
transport through arterial tissue have typically in-
cluded diffusion, convection and binding phenom-
ena.23,62 Finally, the third category includes models
which couple drug release with tissue distribution and
these show the most promise in terms of simulating
in vivo experimental results. Various levels of com-
plexity have been employed with the extension to
2D6,10,76 and 3D models,41,65,71,78 the inclusion of an-
isotropic diffusion properties,76 and the development
of sophisticated nonlinear saturable binding models.64
Whilst simpliﬁed 1D models can provide useful in-
sights, ultimately 3D coupled models which capture
the full complex geometry of the stent and the arterial
wall are likely to be required. The existing 3D models
all make certain simplifying assumptions, such as ide-
alising the stent geometry, neglecting convection, dif-
fusion or binding, in considering only single or bi-layer
arterial walls, or neglecting underlying disease. Nev-
ertheless, mathematical and computational mod-
elling have emerged as useful tools for gaining
important insights into the drug release and tissue
distribution processes, informing device design, and in
helping ascertain the numerous parameters of the
increasingly complex models. As a result, mathemati-
cal and computational modelling will likely go hand-
in-hand with a combination of in vitro, ex vivo and
in vivo experiments in advancing the design of the
stents of the future.
MODELLING IMPACT OF ATHEROSCLEROSIS
ON DRUG RELEASE AND DISTRIBUTION
The majority of models described above fail to
adequately capture the eﬀects of disease, speciﬁcally
the presence of atherosclerotic plaque, on drug release
and distribution. This may be an important limitation,
given that emerging evidence suggests that drug levels
achieved within the artery wall following stenting are
inﬂuenced by variations in plaque structure, composi-
tion and receptor distributions.63 Recent advances in
intravascular imaging reveal that plaque structure and
characteristics can be quite variable from patient to
patient,25,26,60 making it likely that drug levels achieved
within the artery wall will vary from patient to patient.
The extent to which this variability impacts on clinical
outcomes remains to be conﬁrmed. To understand this
more fully, there is thus a need to incorporate varia-
tions in plaque structure and composition into the
existing models used in the investigation of stent-based
drug delivery. We will therefore now go on to review
the current methods available for investigating the
impact of disease severity on coronary stent drug re-
lease and distribution.
In Vitro
In recent years, a variety of approaches to incor-
porate the eﬀects of disease into in vitro models of stent
drug release have been developed. Such approaches
have largely involved the modiﬁcation of previously
established in vitro models. The vessel simulating ﬂow
through cell model ﬁrst described by Neubert et al.46
was adapted to assess the utility of this system to
incorporate hydrophobic regions within the hydrogel.
Hydrogels were modiﬁed using oil droplets or
hydrophobic microparticles, to produce a material
more relevant to the in vivo/disease situation.58 This
initial study measured the partition coefﬁcient, the
ratio of drug content within the gel compartment and
drug within the surrounding solution, of two model
drugs, hydrophilic ﬂuorescein and hydrophobic tri-
amterene, in the hydrogels incubated in drug solutions.
This modiﬁcation had no effect on the partition coef-
ﬁcient of ﬂuorescein; however the partition coefﬁcient
of triamterene was sensitive to the gel modiﬁcation and
increased 3- to 5-fold dependent on the modifying
agent. Despite this there was no change in release rate
or uptake of either molecule when these gels were
incorporated into the vessel simulating ﬂow cell. This
was likely due to the stent polymer coating which
controlled the release. Indeed, further examination of
the data using ﬁnite element analysis was in agreement
with the distribution pattern of triamterene when a fast
release from the stent coating was assumed.58
The artiﬁcial vessels used thus far have been gen-
erally composed of alginate. However, recent attempts
have been made to better mimic the properties of the
sclerotic vessel wall by using gelatin to mimic collagen
and physiologically relevant lipids to emulate lipid la-
den plaques in phantom vessels.18 In these experi-
ments, phantom vessels were housed in syringes and
the surface exposed to solutions containing hydrophilic
tetracycline, or hydrophobic ﬂuvastatin, for a period of
three or four days respectively. Some aspects of drug
transport were found to be dependent upon the com-
position of the phantom vessels, with the nature of
such dependency being dependent on the physical
properties of the drugs investigated. For example, the
diffusion coefﬁcient of the hydrophilic tetracycline was
dependent on the gelatin concentration, and decreased
as gelatin concentration increased, although was lar-
gely independent of lipid concentrations. The future
use of such models should therefore ensure careful
selection of the collagen level of the artiﬁcial plaque so
that it closely matches that found within diseased
human vessels. In contrast to tetracycline, ﬂuvastatin
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transport was strongly dependent on lipid concentra-
tion, displaying decreased diffusivity at elevated lipid
concentrations. The precise effect of lipid concentra-
tions on drug transport therefore appears to be
dependent on the physicochemical properties of the
drug. In the same study by Guo et al.18 the ﬂuvastatin
partition coefﬁcient increased with increasing lipid
concentrations within the gel. This ﬁnding is in con-
trast to those reported by Tzafriri et al. (2010)63 who
found an inverse relationship between lipid content
and the partition coefﬁcients of paclitaxel, everolimus
and sirolimus in human (paclitaxel only) and rabbit
atherosclerotic aortas. The observed differences
between these studies may be due to physicochemical
differences in the drugs under investigation in each
study, although it is also likely to be a reﬂection of the
increased complexity of the ex vivo tissues63 over the
phantom vessels,18 where binding of drug to speciﬁc
sites was neglected. Therefore, although important
information on drug transport can be found from
current artery mimics, the lack of cell speciﬁc binding
within such models remains a key limitation. However,
their ability to study the effects of particular compo-
nents of the plaque in a controlled and systematic
manner, mean that they will be useful for providing
mechanistic insights into the how the transport of
different drug types are likely to be differentially af-
fected within atherosclerotic vessels.18
In Vivo
Pig
There are a number of pig models available which
develop atherosclerosis in response to a high fat diet.
Lesions develop around 6 months, mainly in the
abdominal aorta and coronary arteries.16,66 Further-
more, a line of pigs, with familial hyperlipidaemia
syndrome (FHS) have been bred that develop
atherosclerosis spontaneously. These pigs develop
coronary lesions within 1 year which are characterised
by fatty deposits and inﬂammatory and SMC inﬁl-
trates, and they progress to more complex lesions
throughout the animals’ lifetime.40,51 Although both
models have been used to evaluate efﬁcacy, with a
potential dose effect indicated in one such study,61 they
have not so far been used for detailed investigations of
drug release and distribution following stenting.
However, the FHS model, combined with balloon ca-
theter induced endothelial denudation, was used in the
evaluation of coated balloon drug delivery to femoral
arteries.17 Zotarolimus was detected within 5 min of
drug delivery in the superﬁcial femoral artery. The
amount of drug had reduced by 24 h though it was still
detectable after 28 days.
Rabbit
The New Zealand White rabbit develops
atherosclerotic plaques when fed an atherogenic high
fat diet either alone or combined with balloon injury.68
Lesions develop throughout the aorta and in the
coronary and iliac arteries by around 12 weeks. The
lesion characteristics and distribution are variable but
are generally restricted to ﬁbrofoamy and ﬁbrous
plaques.44 This model may therefore be useful for the
consideration of the contribution of these plaque types
to drug release and tissue distribution in vivo. Initial
studies in the atherosclerotic rabbit iliac artery con-
ﬁrmed ﬁndings in humans regarding ISR, where three
different DES signiﬁcantly reduced neointima thickness
and cellular proliferation compared to bare metal stents
(BMS). Additionally, re-endothelialisation was im-
paired with DES compared to BMS. These outcomes
compare favourably to the situation in human disease,
whereas previous studies using healthy arteries from
rabbits failed to detect this difference.44 The rabbit
model of atherosclerosis has yet to be used for the
evaluation of drug uptake and distribution. Nonethe-
less, a number of studies have assessed DES efﬁcacy in
this model and have shown important similarities to
many aspects of the human response to stenting.21,74
Ex Vivo
Examination of tissue ex vivo has been shown to be
particularly useful in determining the impact of tissue
components and physiological transport mechanisms
on drug release and distribution following stenting.
Building on the models described earlier,9,23 Tzafriri
et al.63 used a variety of excised vessels containing
plaque to investigate the extent to which various
components of disease, including alterations in tissue
composition and drug-speciﬁc receptor distributions,
impact upon drug transport. Samples of human aorta
were obtained post-mortem from four donors and all
had some degree of necrotic and calciﬁc regions within
plaques, which also contained moderate to high levels
of lipid. Partition coefﬁcients for sirolimus, paclitaxel
and everolimus were evaluated in a lightly calciﬁed
sample, which was separated into its tunic layers and
immersed in solutions of the drugs for 96 h. Within all
three layers drug deposition was dependent on lipid
content (see Fig. 3). To further validate these ﬁndings
the authors calculated the partition coefﬁcient of the
medial layer of healthy calf carotid arteries which had
lower lipid content than the human samples, and
subsequently the partition coefﬁcient was higher.
Overall these ﬁndings were contrary to the previously
held expectation that hydrophobic drugs would be
better retained in a lipid rich environment.15,37
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In the same study,63 to further investigate the drug
distribution pattern seen in the human tissue, a rabbit
model of atherosclerosis, induced through varying
degrees of dietary cholesterol and balloon injury, was
utilised to produce lesions characterised by predomi-
nantly lipid lesions or more advanced sclerotic lesions.
Net partition coefﬁcient was unaltered in the injured
arteries compared to control arteries for all drugs, with
both drug loading time and equilibrium reached at
similar points. However, ﬂuorescently labeled pacli-
taxel accumulated in regions of lower lipid content in
diseased arteries, similar to the human tissue. Fur-
thermore, paclitaxel distribution was altered in the
injured rabbit model when compared to controls
(Fig. 4). Staining of the tissue indicated that tubulin,
the target of paclitaxel, was reorganised in the diseased
vessels and accumulated towards the medial layer
where partition coefﬁcient was highest. Despite the
relationship between lipid and partition coefﬁcient in
the human sample, there was no alteration in distri-
bution of everolimus in the rabbit tissues. Further-
more, FKBP12 expression was unchanged by the
introduction of injury indicating that drug retention
was dependent on the location and availability of
speciﬁc binding sites rather than the presence of lipid.63
Overall, this study has highlighted the important ef-
fects that speciﬁc binding sites have on drug distribu-
tion following local arterial delivery. Given that altered
distribution of such binding sites appears to accom-
pany atherosclerosis, such effects should be incorpo-
rated into future models used in DES development so
that they better account for the presence of disease.
Computational Models
Despite the progress that has been made, very few of
the existing computational approaches incorporate dis-
ease states. Of the models that do, idealised geometries
and plaque characteristics have been assumed as there
has been no eﬀective way of incorporating real patient
speciﬁc information into such models. In one of the ﬁrst
models of drug distribution through atherosclerotic
plaque, McGinty et al.36,37 incorporated a highly sim-
pliﬁed model of plaque into their 1D coupled drug re-
lease and tissue distribution model. Plaque was assumed
to be homogenous, with a ﬁrst order reaction kinetics
model adopted to account for possible drug binding.
Bozsak et al.6 accounted for disease by modelling a
thickened sub-endothelial space. Most recently, Ferreira
et al.14 accounted for disease by including the stiffness of
the arterial wall in their model, and increasing the stiff-
ness to simulate a diseased arterial wall. An important
factor that has limited the incorporation of disease into
computational models is the limited availability of the
required parameters, with the majority of those in the
literature derived from healthy vessels. There is thus a
need to measure these parameters in diseased vessels and
with the use of some of the modiﬁed in vitro and ex vivo
models described earlier, this is now becoming a realistic
ambition. Equally, the emergence of enhanced
intravascular imaging techniques may help enable the
development of computational models of stent drug re-
lease with more realistic lesion geometries.42
Conclusions and Future Directions
The models described in this review have played an
important role in DES research and development over
many years. The insights they have provided have
FIGURE 3. Partition coefficients of everolimus (blue), pacli-
taxel (red) and sirolimus (green) in atherosclerotic human
aorta. Partition coefficient was greatest in the medial layer
(left) where lipid content was lowest, whilst it was lowest in
the intimal layer (right) where lipid content was most abun-
dant. These data were obtained from a single sample dis-
sected into three tunic layers, cut into 12 sections, and
immersed in drug solution for 96 h (n 5 3 for each layer and
drug). Figure adapted from Tzafriri et al. 2010.63
FIGURE 4. Distribution of paclitaxel across the vessel wall in
an atherosclerotic rabbit aorta. Arteries incubated in paclitaxel
displayed an altered distribution pattern compared to control
tissues. The partition coefficient was determined in 20 lm thick
tissue sections spanning the intimal to adventitial side of the
vessel (n 5 3). Figure adapted from Tzafriri et al. 2010.63
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helped establish a greater understanding of the key
elements governing stent drug release and distribution,
information that has been crucial to the development
of existing drug release proﬁles and which will
help inform the development of enhanced devices in
future.
It is clear from current models that drug release and
tissue uptake from DES is dependent on a number of
factors. In vitro and ex vivo models have highlighted
that the drug physicochemical properties, release
medium, the drug coating and the presence of ﬂow can
all have important effects on drug release and distri-
bution. It is also becoming clear that drug uptake and
release is altered by the presence of atherosclerosis.
Indeed, in vitro and ex vivo experiments have shown
drug partitioning to be greatly affected by the presence
of lipid, with the availability and distribution of
speciﬁc and non-speciﬁc drug binding sites also critical
in this respect.
However, certain limitations remain and it is clear
that there are signiﬁcant opportunities to advance on
current approaches. Both in vitro and in vivo models
fail to fully emulate the human condition67 and can
only provide information on drug release and uptake
at a limited number of time points, often at great ex-
pense and with high technical challenge. Whilst
mathematical and computational models can help ad-
dress some of these limitations, current approaches in
this area have still generally assumed idealised vessel
geometries and compositions, meaning that they do
not adequately incorporate the important effects of
disease that have been revealed by ex vivo studies. In
part, this has been due to the lack of reliable model
parameters obtained from diseased vessels. However,
the measurement of such parameters has now begun.63
In addition, the use of rodent models of atherosclerosis
such as the apolipoprotein E knockout (ApoE2/2)
mouse provides opportunities to carry out large scale
statistically powerful studies, which may help acceler-
ate progress in this emerging research area.12,43,53 In-
deed, many models of stenting, using miniaturised
stents, have been described in the mouse with many
hallmarks of the human disease.1,11,59 Furthermore,
the Watanabe heritable hyperlipidaemic rabbit, which
is a well characterised model of atherosclerosis, dis-
plays a myriad of lesion types and may prove a useful
tool in advancing this research.13 When taken together
with advances in intravascular imaging, there is thus
the opportunity to better inform the development of
computational models that are more closely aligned to
the disease state. Ultimately, such approaches should
increasingly be used to help further our understanding
of the impact of disease on stent-based drug release
and distribution, thus helping in the development of
more effective DES in future.
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